Immunodiagnostic Systems Share Discussion Threads

[74tom] 12/6/2020 08:33

It’s not at a higher valuation because the company appears dire at communicating, and the share is horrendously illiquid. Interested to see where the share price is by this afternoon...

[letmepass] 12/6/2020 08:26

News will be flowing over the weekend. Well done holders

[wigwammer] 12/6/2020 08:23

A quantitative test, not yes/no.. a gold standard?

[wigwammer] 12/6/2020 08:23

So that's 10000 tests per month on 600 systems = 6m tests

[2toptrader] 12/6/2020 08:22

Bought a few as well, awful spread.The co has c £27 mil cash and a differentiated, quantitative approved test. Should be interesting.

[wigwammer] 12/6/2020 08:21

They have kept this totally under their hat..

[farukequity] 12/6/2020 08:20

speechless

[letmepass] 12/6/2020 08:19

100% accuracy... Not bad. Only 50 million mcap

[wigwammer] 12/6/2020 08:08

They've beaten omega and it's a quantitative test..

[wigwammer] 12/6/2020 08:05

600 machines at 10000 tests a month? Doesn't sound limited.

[74tom] 12/6/2020 08:04

Well they’ve beaten Omega! However I’m not buying shares given how illiquid they are - fully expect a seller to come out of the woodwork. Also don’t like the fact the tests can only be run on 600 machines worldwide - that limits their potential somewhat. But hey, at least they have an approved product...

[gwr7] 26/4/2020 09:12

You backed the wrong horse Mr Tiggywinkle. Go back to your hibernation and stop trying to deramp Omega. You're making yourself look silly.

[wigwammer] 26/4/2020 08:51

Hi HH. This is not a manufacturing company. They place testing machines and sell assays to test for various conditions - including infectious diseases - from saliva, blood and urine. Dan is right - this is not a spivvy company - it has considerable scale and scientific capability. So what on earth are management doing? They appear neither energised to develop assays for CV themselves, and if technology is the issue - why have they not used the £30m cash that has sat on the balance sheet for years, to fill gaps in their capability? The smaller players are evidently running rings around them. Bottom line - the U.K's self professed "immunological diagnostics" specialist is doing jack sh1te during the biggest step change in immunological diagnostic management in decades. Perhaps the market will eventually push this higher - just the name will be enough to trick many - but by all accounts, it won't have anything to do with the actions of management up to this point. Atb

[hedgehog 100] 25/4/2020 16:47

Guys,

Immunodiagnostic's current COVID-19 offering is a 'picks & shovels' play.

And remember where that phrase comes from

During the California Gold rush in the 19th century the most reliable way to get rich was reportedly to sell picks and shovels etc to the gold prospectors, rather than actually staking a claim.


"Manufacturing Support for COVID-19

Manufacturing Support

As the world struggles to contain the novel coronavirus (COVID-19) outbreak, it becomes clear that diagnostics test availability is a key constraint. To support our healthcare systems with this challenge, we need to rapidly move production resources into this area.

We at Immunodiagnostic Systems (IDS) want to play a part in the global effort fighting this pandemic. Therefore, we would like to offer our expertise and support in manufacturing ELISA kits for those companies with a COVID-19 diagnostic test that need more production capacity.

What we can provide

IDS is a leading in vitro diagnostic solution provider to the clinical laboratory market. We develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients.

We can offer large scale ELISA plate production, from initial formulation to packaging, labelling and shipment in our ISO 13485 and cGMP qualified facilities in Italy and the United Kingdom.

If you would like to learn more about how we can support your manufacturing efforts or require further information, please contact us on [e-mail].

Let’s work together and make the world a safer place."




"ELISA

... The enzyme-linked immunosorbent assay (ELISA) ... has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries.

In the most simple form of an ELISA, antigens from the sample are attached to a surface. Then, a matching antibody is applied over the surface so it can bind to the antigen. This antibody is linked to an enzyme, and in the final step, a substance containing the enzyme's substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change. ..."




Mass diagnostic testing SHOULD be a game changer in the fight against coronavirus, but there's a global shortage of production capability for this.

IDH is helping to address this, so this SHOULD be a game changer for the company.

Indeed it's a major, lasting business opportunity for IDH, which is clearly moving fast to address this opportunity.

For multiple existing partners, and multiple new partners:

17/04/2020 16:35 UKREG Immunodiagnostic Systems Hldgs PLC FY20 Trading Update
" ... We are offering our production facilities, and sales network, to several new and existing partners who are in the process of developing COVID-19 test kits. ..."

[wigwammer] 25/4/2020 04:34

FFS... we are living through the most profound period of growth for diagnostics relating to the immune system and "immunodiagnostics plc" just plods along as though nothing is happening - losing £1m cash every year and giving themselves a good pat on the back that it isn't losing £2m a year... DO SOMETHING!!

[dan_the_epic] 22/4/2020 18:36

Awful ramping hedgehog. The only things these guys have said they are doing is ELISA plate production. Production of glass plates. Great, that'll be a game changer. Wow. Must buy immediately!


hxxps://www.idsplc.com/uncategorised/covid19support/

[hedgehog 100] 22/4/2020 16:59

IDH is a very substantial company, which is looking massively undervalued given the current shortage of COVID-19 testing capacity.

Here are the IDH figures:

Full year revenue for year ending 30.3.20: £39.3M. (an increase on 2019).
Cash at 31.3.20: £27.6M. (an increase on the year).


Current market cap. at 225p: £64.76M.
Less cash, = £37.16M. for the business above cash levels.
I.e. a revenue multiple of under one times revenue.


Omega Diagnostics (ODX) in comparison:

Half year revenue of £4.46M., a fall from previous first half.
As at 30.9.19: No net cash. Net current liabilities £3M.
Half year loss of £0.29M.


Current market cap. at 32p: £48.58M.
I.e. a revenue multiple of over five times annualised revenue.

[hedgehog 100] 22/4/2020 15:44

IDH is a former 20-bagger.

And it has plenty of facilities and cash to help address the COVID-19 testing shortage.

This could fuel another great period of share price performance.

[hedgehog 100] 22/4/2020 15:16

Speaking of Omega Diagnostics, its share price has been doing rather well recently, multibagging from 7.625p at the start of this month to its current share price of 31p.

Fueled by announcements that it is to manufacture COVID-19 tests.

And IDH looks like it will also be entering into such agreements shortly, judging from its recent trading update.

But the market doesn't seem to have picked up on this yet.

Probably because IDH is currently 'under the radar screen' of most investors, and the RNS was released after close on Friday (17th. April).


17/04/2020 16:35 UKREG Immunodiagnostic Systems Hldgs PLC FY20 Trading Update

" ... Cash position

Closing cash and cash equivalents were GBP27.6m at 31 March 2020 (31 March 2019: GBP27.7m).

... Looking forward

So far in April 2020 we have seen a reduction in revenue versus the same period last year, caused by a reduction in routine medical testing in hospitals and laboratories as their focus has been on COVID-19 treatment and testing. IDS intend to take appropriate action, including utilising the various schemes available from governments to provide business support, to minimise our costs during this period of uncertainty. From a liquidity perspective, IDS is in a very strong position with cash holdings of almost GBP28m.

We are offering our production facilities, and sales network, to several new and existing partners who are in the process of developing COVID-19 test kits. ... "

[upomega] 02/12/2019 19:51

Maybe to do with omega Diagnostic assays